New BTK inhibitors bring light to the treatment of blood tumors

Medicine Network December 28 - Recently, reporters from the 62nd annual meeting of the American Society of Hematology (ASH) learned that Bruton tyrosine kinase (BTK) inhibitor Aubutinib for recurrence / refragrant sleeve lymphoma (MCL) and recurring / refractic chronic lymphoblastic leukemia (CLL ) / small cell leukemia (SLL) in two clinical studies have shown good overall remission rate and safety.
in a study of patients with relapsed/refrmmune chronic lymphoblastic leukemia/small lymphocyte lymphoma (R/R CLL/SLL), a total of 80 patients were admitted to the clinical trial, most of whom were in the advanced stages of the disease, with a medium follow-up time of 14.3 months.
the IRC, the total mitigation rate (ORR) was 91.3 per cent, of which the total mitigation rate (CR) was 10.0 per cent, the partial mitigation rate was 63.8 per cent and the partial remission rate with lymphocyte growth was 17.5 per cent.
" can be said to have a higher rate of complete remission, long-lasting remission and improved safety in the treatment of patients with R/R CLL/SLL.
as a highly selective BTK inhibitor with good pharmacodynamics and pharmacological properties, abtinib provides better treatment options for patients and is expected to be an excellent choice for combined therapy.
Wei, deputy director of the hematology department at Jiangsu Provincial People's Hospital, said most adverse events were mild to moderate, and time-extended follow-up analysis found no new safety problems.
other multi-center, open, clinical Phase II study is the long-term safety and stability of aubusterinib monotherapy recurrence/resuscable heterocellular lymphoma (R/R MCL) in Chinese patients.
106 patients in the study, with a medium follow-up time of 16.4 months, most of whom were in the advanced stages of the disease.
the Lugano Standard (2014), the overall remission rate was 87.9 per cent and 93.9 per cent of patients achieved disease control. the
study found that ebutinib showed consistent efficacy in treating patients with R/R MCL and did not develop level 3 or more of atrial fibrillation/atrial paracels, bleeding, or diarrhea associated with treatment, which supported aubutrini as a better option for BTK inhibitor therapy.
, deputy director of lymphoma at Peking University Cancer Hospital, said adverse events include plateiac reduction, neugenic granulocyte reduction, leukocyte reduction and high blood pressure.
In addition, the reporter also learned that the current 5 studies of abtinib, covering a total of 266 patients, preliminary safety results show that compared with other BTK inhibitors, abtinib BTK off-target-related adverse events (such as atrial fibrillation /atrial paracelod, diarrhea, etc.) are less likely.
it is learned that Abtini is a class 1 innovative drug developed by Novartar Jianhua, mainly used to treat lymphoma and autoimmune diseases, and access to the country's major new drug creation project support.
。